Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C38H61N3S3.2I |
| Molecular Weight | 909.915 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[I-].[I-].CCCCCCCN1C(C)=CSC1=CC=C(C=CC2=[N+](CCCCCCC)C(C)=CS2)C3=[N+](CCCCCCC)C(C)=CS3
InChI
InChIKey=BHSBKKSKODCAAS-UHFFFAOYSA-L
InChI=1S/C38H61N3S3.2HI/c1-7-10-13-16-19-26-39-32(4)29-42-36(39)24-22-35(38-41(34(6)31-44-38)28-21-18-15-12-9-3)23-25-37-40(33(5)30-43-37)27-20-17-14-11-8-2;;/h22-25,29-31H,7-21,26-28H2,1-6H3;2*1H/q+2;;/p-2
| Molecular Formula | C38H61N3S3 |
| Molecular Weight | 656.106 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Optical Activity | NONE |
| Molecular Formula | HI |
| Molecular Weight | 127.91241 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17436564Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25791838 | https://www.ncbi.nlm.nih.gov/pubmed/26050653 | https://www.ncbi.nlm.nih.gov/pubmed/16643232 | https://www.ncbi.nlm.nih.gov/pubmed/28165057
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17436564
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25791838 | https://www.ncbi.nlm.nih.gov/pubmed/26050653 | https://www.ncbi.nlm.nih.gov/pubmed/16643232 | https://www.ncbi.nlm.nih.gov/pubmed/28165057
Platonin (4,4'-dimethyl-3,3'-di-n-heptyl-8-[2-(4-methyl-3-n-heptylthiazole)] -2,2'-dicarbocyanine diiodine) is one of the photosensitive trithiazolepentamethine cyanine dyes, with antioxidant, anti-inflammatory and anticancer activity. Platonin had also effects in rat models of endotoxemia which may have been mediated by a reduction of mean arterial blood pressure and inhibition of NO and free radical formation. Platonin inhibited the production of pyrogenic cytokines from human peripheral blood mononuclear cells (PBMC), resulting in antipyresis. Lipopolysaccharide (LPS) was shown to induce NF-kappaB activation of PBMC, and this effect was abolished by Platonin. Platonin is thus a potent macrophage-activating agent and immunomodulator. Platonin potently inhibited platelet aggregation and c-Jun NH2-terminal kinase (JNK) phosphorylation in collagen-activated platelets. The anti-aggregation effect did not affect bleeding time but increased occlusion time in platonin-treated mice. Platonin was potent in diminishing collagen- and Fenton reaction-induced ∙OH formation. Platonin exhibited remarkable neuroprotective properties against MCAO-induced ischemia in a mouse model through its antiaggregation, anti-inflammatory and antiradical properties.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: WP1884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28165057 |
|||
Target ID: GO:0007258 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28165057 |
|||
Target ID: GO:0032496 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28165057 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28165057 |
Primary | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25791838
A total of 72 adult male rats (200e250 g) were randomized to receive cecal ligation and puncture (CLP), CLP plus platonin, sham operation, or sham operation plus platonin (n ј 18 in each group). Platonin (100 mkg/kg; Kankohsha Co., Osaka, Japan; dissolved in a mixture of 0.5 mL normal saline) was injected via the tail vein immediately after cecal ligation and puncture. Systemic inflammation and oxidation levels and BBB integrity in the surviving rats were determined after 24-hour monitoring
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16643232
Five groups of confluent murine macrophages (RAW264.7 cells) were randomly allocated to receive a 1-h pretreatment of one of five doses of platonin (0.1 mkM, 1 mkM, 10 mkM, 100 mkM, or 1000 mkM) followed by lipopolysaccharide (LPS; 100 ng/ml). For negative, positive, and platonin control, three other groups of cell cultures were randomly allocated to receive phosphate-buffered saline, LPS, or platonin (1000 mkM). The cultures were harvested after exposing them to LPS for 18 h or a comparable duration in those groups without LPS. NO production, L-arginine transport, and expression of the relevant enzymes were then evaluated.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:26:55 GMT 2025
by
admin
on
Mon Mar 31 18:26:55 GMT 2025
|
| Record UNII |
0X9JDS6MF1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000024247
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
DTXSID40957120
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
9854359
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110591
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
C032149
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
3571-88-8
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
0X9JDS6MF1
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
222-681-5
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
C74205
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | |||
|
m8915
Created by
admin on Mon Mar 31 18:26:55 GMT 2025 , Edited by admin on Mon Mar 31 18:26:55 GMT 2025
|
PRIMARY | Merck Index |